Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
Open Access
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5), 979-993
- https://doi.org/10.1007/s00280-020-04073-5
Abstract
Purpose Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2 '-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor types for which tumor suppressor gene methylation is potentially prognostic. To obtain pharmacodynamic evidence for DNMT inhibition by FdCyd, we developed a novel method for detecting expression of tumor suppressor protein p16/INK4A in circulating tumor cells (CTCs). Methods Patients in histology-specific strata (breast, head and neck [H&N], or non-small cell lung cancers [NSCLC] or urothelial transitional cell carcinoma) were administered FdCyd (100 mg/m(2)) and THU (350 mg/m(2)) intravenously 5 days/week for 2 weeks, in 28-day cycles, and progression-free survival (PFS) rate and objective response rate (ORR) were evaluated. Blood specimens were collected for CTC analysis. Results Ninety-three eligible patients were enrolled (29 breast, 21 H&N, 25 NSCLC, and 18 urothelial). There were three partial responses. All strata were terminated early due to insufficient responses (H&N, NSCLC) or slow accrual (breast, urothelial). However, the preliminary 4-month PFS rate (42%) in the urothelial stratum exceeded the predefined goal-though the ORR (5.6%) did not. An increase in the proportion of p16-expressing cytokeratin-positive CTCs was detected in 69% of patients evaluable for clinical and CTC response, but was not significantly associated with clinical response. Conclusion Further study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement.Funding Information
- Division of Cancer Treatment and Diagnosis, National Cancer Institute (ZIA BC 011078; Phase 0/1 Clinical Trials)
This publication has 57 references indexed in Scilit:
- Concise Drug Review: Azacitidine and DecitabineThe Oncologist, 2013
- Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast CancerClinical Breast Cancer, 2012
- Breast Cancer Methylomes Establish an Epigenomic Foundation for MetastasisScience Translational Medicine, 2011
- DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic typeLung Cancer, 2010
- Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor CellsClinical Cancer Research, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinomaBritish Journal of Cancer, 2008
- Frequently Methylated Tumor Suppressor Genes in Head and Neck Squamous Cell CarcinomaCancer Research, 2008
- Epigenetic Regulation as a New Target for Breast Cancer TherapyCancer Investigation, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerThe New England Journal of Medicine, 2004